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and also allowed for the direct discharge from the emergency
room. At the same time, there was no decrease in the overall
cost of care and increased radiation exposure.
Now putting these results in proper perspective, the
patients of ROMICAT II had an average age of 54 years, 47%
were women, all had normal ECG’s and all had normal
troponin levels. With all these parameters, the probability of
occurrence of coronary artery disease itself is so low that
whether one needs to do further testing at all in these patients
can be questioned and most definitely cannot be recom-
mended as a general policy for all. Most of us would probably
not ask for any investigations beyond a few hours of obser-
vation, some serial ECGs and a troponin level at the end of it
all!
If you want to consider this from country wise perspective
then for a country like the USA where even one missed
coronary event can lead to a lawsuit, protective medicine will
probably result in this study leading to CTA becoming part of
the emergency room protocols for chest pain. This type of
protective medicine fortunately is not yet practiced in India.
If we look at the cost of care of chest pain (excess of Rs 2
lakhs!), then perhaps a CTA within a few hours of admission
cutting down the cost of admission could be one new way of
looking at this issue but then this was not the question
addressed in this study.
At the same time one should not discount the utility of
coronary CT angiography in select situations in the emer-
gency room, where you want to be very confident about the
coronary anatomy (e.g. VIP or faculty colleague or relative) or
where a patient keeps coming back and will not be convinced
without a normal report, then a CTA is the answer.
So, in conclusion, in most situations especially as a public
policy, simple observation and clinical testing would be better
than CTA, though a CTA should always be available for
selected situations.
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“By failing to prepare you are preparing to fail.” e Benjamin
Franklin
Intra-aortic balloon counter-pulsation (IABP) is one of the
most commonly used haemodynamic support device in the
setting of haemodynamic instability complicating myocardialinfarction. IABP support gets class I recommendation for this
condition even though the evidence for such recommenda-
tion is scarce. In the IABP SHOCK II trial 600 patients with
acute myocardial infarction and cardiogenic shock under-
going early revascularization were randomised to IABP and no
IABP. IABP use was not associated with any significant
difference in the 30-day mortality or hospital stay. At 30 days,
39.7% of the IABP patients and 41.3% of controls had died
( p ¼ 0.69). Interestingly, there was no IABP related side effects
in the IABP group. Most of the patients (86.6%) received IABP
immediately after the procedure and 10% patients in no IABP
arm crossed over to IABP arm. There was no difference in the
primary end point of mortality among the various subgroups
of age, gender, type of MI and blood pressure.
Major limitations in this study as discussed in the accom-
panying editorial were a relatively smaller sample size and
a lower mortality rate as compared with other contemporary
trials. This makes it a relatively moderate risk group where
benefit of IABP may be lower than in high risk patients. A 10%
crossover rate is another limiting factor, although on treat-
ment analysis after accounting for the crossover, also failed to
prove benefit for IABP use.
Perspective
Fifty years after first technical demonstration of the utility of
IABP at the Cleveland clinic, several serious questions are
being raised regarding the efficacy of IABP. Although IABP is
a class I recommendation for refractory cardiogenic shock as
per ACC/AHA and ESC guidelines, the evidence for the use of
IABP ismainly from small randomised studies or retrospective
analysis. The basic haemodynamic principle of IABP is
improvement in diastolic coronary perfusion and systolic
unloading of the heart. Intuitively this principle appears quiet
promising in the setting of STEMI with cardiogenic shock but
has failed on clinical grounds. A meta-analysis published in
2009 also failed to show any benefit for IABP in the setting of
primary PCI with cardiogenic shock.
Twomore trials published recently have failed to show any
benefit for IABP in the setting of anterior wall STEMI and
complex PCI. Counter-pulsation to Reduce Infarct Size Pre-
PCI-Acute Myocardial Infarction (CRISP-AMI) trial rando-
mised 337 patients with stable AWSTEMI who underwent
primary PCI with/without IABP support. There was no differ-
ence in the 30-day and 6 months death or MI rates between
the two groups. Assessment of infarct size by cardiac MRI 4
days after MI was also not different. Second trial, Balloon-
Pump Assisted Coronary Intervention Study (BCIS)-1 rando-
mised patientswith low EF and undergoing PCI, to IABP and no
IABP. It had shown no difference in the risk of major adverse
cardiac and cerebrovascular events (MACCE) at the time of
hospital discharge among patients treated with IABP when
compared with those who did not receive counter-pulsation.
However, long term results of this study after a median follow
up of 51 months have shown a 34% reduction in themortality.
The three trials mentioned earlier have studied the utility
of IABP in complex PCI, STEMI and cardiogenic shock, with
none of them supporting the use of IABP in these conditions.
Registry data from Cath-PCI registry has shown no difference
i n d i a n h e a r t j o u r n a l 6 4 ( 2 0 1 2 ) 6 1 4e6 1 9618in the outcomes among the hospitals with frequent use of
IABP for complex PCI versus hospitals with less use of IABP.
This registry has analysed data from more than 180,000
patients who underwent complex PCI with use of IABP in
about 19,000 (10.5%) procedures.
Although, believers of IABPmay have one or other criticism
for these trials but the fact remains that these are (especially
IABP SHOCK II) large randomised trials and they have failed to
show benefit of IABP use consistently. These results will have
impact on the IABP usage in the coming years and researchers
will have to look for new protocols/algorithms to decide about
the need for IABP in a particular patient. The only comforting
point for IABP use is that there were no IABP related compli-
cations. This will give IABP users some leverage to use it on
a case to case basis as it is not doing any harm.
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Objectives: The goal of this study was to compare angio-
graphic, intravascular imaging, and functional parameters, as
well as the clinical outcomes of patients treated with drug-
eluting balloon (DEB) plus bare-metal stent (BMS) versus
BMS versus drug-eluting stent (DES) for ST-segment elevated
acute myocardial infarction (STEMI).
Background: Concerns remain regarding the long-term
safety of DES in STEMI. DEB could provide an attractive
alternative in order to achieve potentially similar effective-
ness but limiting the long-term hazards related to late-
acquired stent malapposition and thus stent thrombosis.
Methods: In this randomized, international,2-center, single-
blinded, 3-arm study, STEMI patients were randomly assigned
to group A: BMS; group B: DEB plus BMS; or group C: DES after
successful thrombus aspiration. The primary endpoint was 6-
month angiographic in-stent late-luminal loss. Secondary
endpoints were in-stent binary restenosis, major adverse
cardiac events (MACE: cardiac death, myocardial infarction,
target vessel revascularization). In a subgroup of patients, stent
(mal) apposition (by optical coherence tomography) and endo-
thelial function (by acetylcholine infusion) was assessed.
Results: Overall, 150 patients were randomized. Procedural
success was achieved in 96.7%. In groups A, B, and C,
respectively, late-luminal loss was 0.74e0.57 mm,
0.64e0.56 mm, and 0.21e0.32 mm (pe0.01); binary restenosiswas 26.2%, 28.6%, and 4.7% (p e 0.01); and MACE rates were
23.5%, 20.0%, and 4.1% (p e 0.02), respectively. The median
percentage [25the75th interquartile range] of uncovered and
malapposed stent struts per lesion was 0 [0e0.35], 2.84
[0e6.63], and 5.21 [3.25e14.5] (pe 0.01). Significant paradoxical
vasoconstriction was seen in groups B and C.
Conclusions: In STEMI patients, DEB followed by BMS
implantation failed to show angiographic superiority to
BMS only. Angiographic results of DES were superior to both
BMS and DEB. Moreover, DEB before implantation induced
more uncovered and malapposed stent struts than BMS, but
less than after DES.
Perspective
The main findings of this randomized, multicentre study are:
1) DIOR DEB failed to demonstrate angiographic superiority
over BMS, with similar late-luminal loss and binary restenosis
rates; 2) DES showed significantly better angiographic and
clinical results compared with both DEB and BMS; and 3) DEB
had significantly more combined uncovered and malapposed
struts compared with BMS, but less compared with the DES
group.
DEB appeared to be an attractive option in the treatment of
STEMI in combination with a BMS because of the following
theoretical advantages: 1) homogeneous distribution of the
drug to the vessel wall, especially at the area of the culprit
plaque, whereas the DES delivers the drug only in the prox-
imity of its struts; 2) better angiographic results, and hence
less need for TLR; 3) less malapposition, with potentially less
stent thrombosis with respect to DES; 4) preservation of
endothelial function with respect to DES; and 5) possibly less
prone to the potential clinical consequences in case of short-
ened dual antiplatelet duration, or in patients incapable of
adhering to 12-month dual antiplatelet therapy. Notwith-
standing these potential advantages, the DEB used in this
study failed to prove superior angiographic outcomes.
Moreover the percentage of uncovered and malapposed
struts as seen on OCT suggest that there is a drug effect
induced by DEB that shows morphological changes compared
with BMS alone. The DES group showed even more
pronounced morphological changes. These results may
suggest that the DEB did induce some effects on neointimal
proliferation as demonstrated by OCT; however, they were
insufficient to cause enough inhibition of the process to
reduce late-luminal loss as compared with the BMS group.
Also, the acetylcholine testing findings in the present study
point toward a drug effect in DEB-treated patients. After
incremental acetylcholine infusions, paradoxical vasocon-
striction occurred in the DEB- and DES-treated patients, with
insignificantly more pronounced vasoconstriction in DEB
compared with DES. By contrast, endothelial function in the
BMS group was stable after incremental acetylcholine
concentrations.
Our opinion
Primary PCI with DES has been shown to be better than BMS in
reducing TLR without an increased risk of stent thrombosis in
